These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 35454385)

  • 1. Eribulin Mesylate Improves Cisplatin-Induced Cytotoxicity of Triple-Negative Breast Cancer by Extracellular Signal-Regulated Kinase 1/2 Activation.
    Ko H; Lee M; Cha E; Sul J; Park J; Lee J
    Medicina (Kaunas); 2022 Apr; 58(4):. PubMed ID: 35454385
    [No Abstract]   [Full Text] [Related]  

  • 2. The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway.
    Ono H; Sowa Y; Horinaka M; Iizumi Y; Watanabe M; Morita M; Nishimoto E; Taguchi T; Sakai T
    Breast Cancer Res Treat; 2018 Aug; 171(1):43-52. PubMed ID: 29752686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subtypes of Triple-negative Breast Cancer Cell Lines React Differently to Eribulin Mesylate.
    Bräutigam K; Mitzlaff K; Uebel L; Köster F; Polack S; Pervan M; Steinert G; Rody A; Liedtke C
    Anticancer Res; 2016 Jun; 36(6):2759-66. PubMed ID: 27272786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HDAC6 inhibition enhances the anti-tumor effect of eribulin through tubulin acetylation in triple-negative breast cancer cells.
    Oba T; Ono M; Matoba H; Uehara T; Hasegawa Y; Ito KI
    Breast Cancer Res Treat; 2021 Feb; 186(1):37-51. PubMed ID: 33452951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models.
    Guo Z; Luo J; Mashl RJ; Hoog J; Maiti P; Fettig N; Davies SR; Aft R; Held JM; Govindan R; Ding L; Li S; von Morze C; Wulf GM; Shoghi KI; Ma CX
    Cancer Res Commun; 2024 Jun; 4(6):1430-1440. PubMed ID: 38717161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of PD-1/PD-L1 and ERK1/2 impede the proliferation of receptor positive and triple-negative breast cancer cell lines.
    Bräutigam K; Kabore-Wolff E; Hussain AF; Polack S; Rody A; Hanker L; Köster F
    J Cancer Res Clin Oncol; 2021 Oct; 147(10):2923-2933. PubMed ID: 34185141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel RAF/MEK inhibitor CH5126766/VS-6766 has efficacy in combination with eribulin for the treatment of triple-negative breast cancer.
    Ono H; Horinaka M; Sukeno M; Morita M; Yasuda S; Nishimoto E; Konishi E; Sakai T
    Cancer Sci; 2021 Oct; 112(10):4166-4175. PubMed ID: 34288272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.
    Gohr K; Hamacher A; Engelke LH; Kassack MU
    BMC Cancer; 2017 Nov; 17(1):711. PubMed ID: 29100507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apatinib enhanced anti-tumor activity of cisplatin on triple-negative breast cancer through inhibition of VEGFR-2.
    Gao Z; Shi M; Wang Y; Chen J; Ou Y
    Pathol Res Pract; 2019 Jul; 215(7):152422. PubMed ID: 31079851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.
    Yoshida T; Ozawa Y; Kimura T; Sato Y; Kuznetsov G; Xu S; Uesugi M; Agoulnik S; Taylor N; Funahashi Y; Matsui J
    Br J Cancer; 2014 Mar; 110(6):1497-505. PubMed ID: 24569463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eribulin Regresses a Cisplatinum-resistant Rare-type Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft Mouse Model.
    Yamamoto J; Murata T; Sugisawa N; Higuchi T; Tashiro Y; Nishino H; Inubushi S; Sun YU; Lim H; Miyake K; Shimoya K; Nomura T; Kurebayashi J; Tanino H; Hozumi C; Bouvet M; Singh SR; Endo I; Hoffman RM
    Anticancer Res; 2020 May; 40(5):2475-2479. PubMed ID: 32366391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitory effects of iron depletion plus eribulin on the breast cancer microenvironment.
    Goto W; Kashiwagi S; Asano Y; Takada K; Morisaki T; Takahashi K; Fujita H; Shibutani M; Amano R; Takashima T; Tomita S; Hirakawa K; Ohira M
    BMC Cancer; 2020 Dec; 20(1):1215. PubMed ID: 33302911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined Aurora Kinase A and CHK1 Inhibition Enhances Radiosensitivity of Triple-Negative Breast Cancer Through Induction of Apoptosis and Mitotic Catastrophe Associated With Excessive DNA Damage.
    Li C; Liao J; Wang X; Chen FX; Guo X; Chen X
    Int J Radiat Oncol Biol Phys; 2023 Dec; 117(5):1241-1254. PubMed ID: 37393021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eribulin Synergistically Increases Anti-Tumor Activity of an mTOR Inhibitor by Inhibiting pAKT/pS6K/pS6 in Triple Negative Breast Cancer.
    Wen W; Marcinkowski E; Luyimbazi D; Luu T; Xing Q; Yan J; Wang Y; Wu J; Guo Y; Tully D; Han ES; Yost SE; Yuan Y; Yim JH
    Cells; 2019 Aug; 8(9):. PubMed ID: 31480338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer.
    Kashiwagi S; Asano Y; Goto W; Takada K; Takahashi K; Noda S; Takashima T; Onoda N; Tomita S; Ohsawa M; Hirakawa K; Ohira M
    PLoS One; 2017; 12(2):e0170634. PubMed ID: 28166544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of predictive markers of the therapeutic effect of eribulin chemotherapy for locally advanced or metastatic breast cancer.
    Kashiwagi S; Fukushima W; Asano Y; Goto W; Takada K; Noda S; Takashima T; Onoda N; Ohsawa M; Hirakawa K; Ohira M
    BMC Cancer; 2017 Aug; 17(1):604. PubMed ID: 28859615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Single Low Dose of Eribulin Regressed a Highly Aggressive Triple-negative Breast Cancer in a Patient-derived Orthotopic Xenograft Model.
    Lim HI; Yamamoto J; Inubushi S; Nishino H; Tashiro Y; Sugisawa N; Han Q; Sun YU; Choi HJ; Nam SJ; Kim MB; Lee JS; Hozumi C; Bouvet M; Singh SR; Hoffman RM
    Anticancer Res; 2020 May; 40(5):2481-2485. PubMed ID: 32366392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft (PDOX) Mouse Model Is Sensitive to Bevacizumab and Vinorelbine, Regressed by Eribulin and Resistant to Olaparib.
    Yamamoto J; Murata T; Tashiro Y; Higuchi T; Sugisawa N; Nishino H; Inubushi S; Sun YU; Lim H; Miyake K; Hongo A; Nomura T; Saitoh W; Moriya T; Tanino H; Hozumi C; Bouvet M; Singh SR; Endo I; Hoffman RM
    Anticancer Res; 2020 May; 40(5):2509-2514. PubMed ID: 32366395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Oral Recombinant Methioninase and Eribulin on a PDOX Model of Triple-negative Breast Cancer (TNBC) Liver Metastasis.
    Lim HI; Sun YU; Han Q; Yamamoto J; Hoffman RM
    In Vivo; 2021; 35(5):2531-2534. PubMed ID: 34410939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eribulin promotes proliferation of CD8
    Shimizu T; Oba T; Oshi M; Ito KI
    Breast Cancer Res Treat; 2024 Jan; 203(1):57-71. PubMed ID: 37733186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.